IQWiG A25-156: Added Benefit Not Proven for Iptacopan in Paroxysmal Nocturnal Haemoglobinuria

IQWiG's March 2026 A25-156 assessment concluded no added benefit proven for iptacopan in PNH due to comparator misalignment in the submitted evidence. The AMNOG decision reflects evidence-design constraints, not absence of clinical effect.